Rapamycin Protects Ova Induced Asthma In Mice Through Regulating Autophagy

D. Yang,Y. Mou,M. Jin
DOI: https://doi.org/10.1183/13993003.congress-2015.PA598
IF: 24.7
2014-01-01
American Journal of Respiratory and Critical Care Medicine
Abstract:Although glucocorticoids and bronchodilators are effective treatment, many asthmatic patients are not well controlled. Autophagy, a form of cell death, remains unknown of its occurrence and roles in the allergic asthma. We hypothesized that the upregulation of autophagy protects against OVA-induced allergic asthma by suppressing airway inflammation. Female BALB/c mice were sensitized and challenged by OVA and treated with intraperitoneal injection of rapamycin, or CQ. Inflammatory cells infiltrated into the peribronchiolar and perivascular connective tissues, total BALF cell count, eosinophils count, the percentage of eosinophils increase with OVA exposure compared with those of the control group. Marked goblet cell hyperplasia, mucus hypersecretion within the bronchi and higher Muc5AC mRNA expression, significantly increased IL-4, IL-13 and TGF-β were demonstrated in OVA exposed mice compared with controls. These elevations were markedly attenuated with rapamycin and CQ treatment compared with the OVA/PBS group. Mice with OVA exposure showed an increased formation of vacuoles in the cytoplasm, increased autophagosomal membrane-bound LC3-II abundance, increased mRNA expression of ATG5 and ATG7. Rapamycin and CQ treatment further increased above autophagy expression as compare with OVA/PBS mice. We then demonstrated the induction and the inhibition of autophagy signal pathways proteins. Rapamycin treatment significantly suppressed OVA induced mTOR expression. CQ treatment resulted in markedly decreased expression of Beclin-1 after OVA exposure. In conclusion, autophagy is properly activated in the lung in a mouse model of OVA induced asthma and appears to play protective roles in asthmatic mice.
What problem does this paper attempt to address?